- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT03732209
A Remotely Delivered Episodic Future Thinking Intervention to Improve Management of Type 2 Diabetes
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
Participants (N = 64) will be randomly assigned to either an episodic future thinking group or control thinking groups. Participants will generate episodic future events or control information, as well as related text-based cues, and will be prompted via smartphone or web application to engage in episodic future or control thinking frequently in their natural environment (e.g., at home or work, before meal times, and in high-risk situations) for a 4-month period. Participants in both groups will be provided with one-on-one, phone-based case management and provided with instructional materials and behavioral tools for weight loss and diabetes management. Instructional materials will include: 1) a modified version of the Traffic Light Diet, which utilizes red, yellow, and green labels for food to guide participants toward the goal of consuming low energy dense, low glycemic, high nutrient dense foods; 2) the Traffic Light Activity Program, which also utilizes red, yellow, and green labels for different levels of caloric expenditure, and 3) tools for self-monitoring of weight, diet, and/or physical activity.
Participants will complete four laboratory-based assessment sessions in which the investigators assess body weight, height, waist and hip circumference, glycemic control (HbA1C), adherence to oral glucose-lowering medication, delay discounting, reinforcing efficacy of food, and blood pressure. These assessments will be completed before the intervention (Week 0), during the intervention (8 weeks), and immediately after the intervention (Week 16), as well after a 2-month post-intervention follow-up (Week 24). The latter three assessments sessions will also include questions to measure participants' perceived effectiveness and ease of use of the intervention. Participants will also complete several remote assessments, including dietary intake and physical activity (during Weeks 0, 8, and 16; via accelerometer), as well as delay discounting and reinforcing efficacy of food (during Weeks 3, 8, and 16).
Studietype
Inschrijving (Werkelijk)
Fase
- Fase 2
- Fase 1
Contacten en locaties
Studie Locaties
-
-
Virginia
-
Roanoke, Virginia, Verenigde Staten, 24016
- Fralin Biomedical Research Institute
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Overweight or obese (BMI of 25 or greater)
- Poorly controlled type 2 diabetes (HbA1C of 8% or greater)
- Prescribed or recommended oral glucose-lowering medication
Exclusion Criteria:
- Current insulin therapy for type 2 diabetes
- History of gestational diabetes
- Pregnant or lactating
- Not ambulatory
- Intellectual impairment
- Unmanaged medical or psychiatric disorder
- Abnormal glucose related to medications (e.g, glucocorticoids)
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Dubbele
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
---|---|
Experimenteel: Episodic future thinking
Participants will generate positive future events and related text cues that will be accessed via an electronic app to engage in episodic future thinking.
|
Participants will engage in episodic future thinking, prompted via text-based cues, when making decisions about dietary, exercise, and medication adherence choices.
|
Sham-vergelijker: Control thinking
Participants will generate non-future-oriented information and related text cues that will be accessed via an electronic app to engage in control thinking..
|
Participants will engage in non-future-oriented control thinking, prompted via text-based cues, when making decisions about dietary, exercise, and medication adherence choices.
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Change in glycemic control
Tijdsspanne: Baseline, 8 weeks, 16 weeks, and 24 weeks
|
Glycemic control will be assessed by hemoglobin A1C (HbA1c), a standardized diagnostic measure for type 2 diabetes.
|
Baseline, 8 weeks, 16 weeks, and 24 weeks
|
Change in weight
Tijdsspanne: Baseline, 8 weeks, 16 weeks, and 24 weeks
|
Body weight will be measured using a digital scale.
|
Baseline, 8 weeks, 16 weeks, and 24 weeks
|
Change in delay discounting
Tijdsspanne: Baseline, 8 weeks, 16 weeks, and 24 weeks
|
Delay discounting will be assessed using computerized behavioral tasks.
|
Baseline, 8 weeks, 16 weeks, and 24 weeks
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Change in dietary intake
Tijdsspanne: Baseline, 8 weeks, 16 weeks, and 24 weeks
|
Dietary intake will be assessed by 24-hour food recall, using the Automated Self-Administered 24 (ASA-24) food recalls.
|
Baseline, 8 weeks, 16 weeks, and 24 weeks
|
Change in medication adherence
Tijdsspanne: Baseline, 8 weeks, 16 weeks, and 24 weeks
|
Medication adherence to oral glucose-lowering medication (e.g., metformin) will be assessed by direct observation (pill counts) and by self-report.
|
Baseline, 8 weeks, 16 weeks, and 24 weeks
|
Change in physical activity
Tijdsspanne: Baseline, 8 weeks, 16 weeks, and 24 weeks
|
Duration of physical activity (in minutes) will be measured using an Actigraph accelerometer
|
Baseline, 8 weeks, 16 weeks, and 24 weeks
|
Change in blood pressure
Tijdsspanne: Baseline, 8 weeks, 16 weeks, and 24 weeks
|
Blood pressure will be measured using an automated blood pressure device.
|
Baseline, 8 weeks, 16 weeks, and 24 weeks
|
Change in waist and hip circumference
Tijdsspanne: Baseline, 8 weeks, 16 weeks, and 24 weeks
|
Waist and hip circumference will be assessed by measuring tape.
|
Baseline, 8 weeks, 16 weeks, and 24 weeks
|
Andere uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Perceived treatment effectiveness and ease of use
Tijdsspanne: 8 weeks, 16 weeks, and 24 weeks
|
Ease of use and perceived treatment effectiveness for each intervention component will be measured using the Ease of Use and Treatment Effectiveness Questionnaire (EUTEQ), a custom-designed questionnaire modified from a previous scale used in treatment for alcohol use disorder.
Scores will be calculated for each intervention component (e.g., episodic thinking, Traffic Light Diet) separately for ease of use and treatment effectiveness.
Scale ranges from 1 (not at all easy to use/effective) to 5 (very easy to use/effective).
Higher scores represent greater ease of use, perceived effectiveness.
|
8 weeks, 16 weeks, and 24 weeks
|
Medewerkers en onderzoekers
Onderzoekers
- Hoofdonderzoeker: Jeff S Stein, PhD, Virginia Tech Carilion School of Medicine and Research Institute
- Hoofdonderzoeker: John W Epling, MD, Carilion Clinic
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- 2696
- 1R21NR018349-01 (Subsidie/contract van de Amerikaanse NIH)
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op Type 2 diabetes
-
University of Trás-os-Montes and Alto DouroVoltooidDiabetes mellitus type 2 | Diabetesgerelateerde complicatiesPortugal
-
Diabetes Foundation, IndiaNational Diabetes Obesity and Cholesterol FoundationWervingDiabetes mellitus type 2 met complicatiesIndië
-
Wang SiqiChina-Japan Friendship HospitalNog niet aan het werven
-
HighTide Biopharma Pty LtdWervingDiabetes mellitus type 2China
-
Nanjing First Hospital, Nanjing Medical UniversityWervingDiabetes mellitus type 2China
-
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.Nog niet aan het werven
-
Beijing Chao Yang HospitalNog niet aan het wervenDiabetes mellitus type 2China
-
Vinmec Research Institute of Stem Cell and Gene...VoltooidDiabetes mellitus type 2Vietnam
-
Eli Lilly and CompanyActief, niet wervendDiabetes mellitus type 2China, Verenigde Staten, Nederland, Spanje, Australië, Oostenrijk, Indië, Canada, Taiwan, Japan, Verenigd Koninkrijk, België, Frankrijk, Duitsland, Mexico, Roemenië, Italië, Argentinië, Brazilië, Puerto Rico, Oekraïne, Hongarije, Tsj... en meer
-
HighTide Biopharma Pty LtdShenzhen HighTide Biopharmaceutical Ltd.Voltooid
Klinische onderzoeken op Episodic future thinking
-
Johns Hopkins UniversityVoltooidDementieVerenigde Staten